Literature DB >> 22773978

Transforming growth factor-β neutralizing antibodies inhibit subretinal fibrosis in a mouse model.

Han Zhang1, Zhe-Li Liu.   

Abstract

AIM: To determine the involvement of the transforming growth factor (TGF)-β with the development of experimental subretinal fibrosis in a mouse model.
METHODS: Subretinal fibrosis was induced by subretinal injection of macrophage-rich peritoneal exudate cells (PECs) and the local expression of TGF-β isoforms was assessed by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) at various time points. In addition, we investigated the effect of TFG-β-neutralizing antibodies (TGFNAb) on subretinal fibrosis development.
RESULTS: TGF-β1 and TGF-β2 mRNA level was significantly elevated at day 2 after subretinal fibrosis induction and increased further to 5 and 6.5-fold respectively at day 5, reaching the peak. TGF-β3 mRNA was not detected in the present study. The result of ELSIA showed that active TGF-β1 and TGF-β2 levels were upregulated to 10-fold approximately, while total TGF-β1 and TGF-β2 levels were even upregulated more than 10-fold and more than 20-fold respectively in subretinal fibrosis mice in comparison with naïve mice at day 5. TGFNAb resulted in a reduced subretinal fibrosis areas by 65% compared to animals from control group at day 7.
CONCLUSION: Our results indicate that TGF-β signaling may contribute to the pathogenesis of subretinal fibrogenesis and TGF-β inhibition may provide an effective, novel treatment of advanced and late-stage neovascular age-related macular degeneration.

Entities:  

Keywords:  subretinal fibrosis; transforming growth factor-β; transforming growth factor-β neutralizing antibody

Year:  2012        PMID: 22773978      PMCID: PMC3388398          DOI: 10.3980/j.issn.2222-3959.2012.03.11

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  30 in total

1.  Transforming growth factor-β inhibition decreases diode laser-induced choroidal neovascularization development in rats: P17 and P144 peptides.

Authors:  Sergio Recalde; Javier Zarranz-Ventura; Patricia Fernández-Robredo; Pío J García-Gómez; Angel Salinas-Alamán; Francisco Borrás-Cuesta; Javier Dotor; Alfredo García-Layana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-09-09       Impact factor: 4.799

2.  Expression of transforming growth factor-beta mRNA in experimental choroidal neovascularization.

Authors:  N Ogata; C Yamamoto; M Miyashiro; H Yamada; M Matsushima; M Uyama
Journal:  Curr Eye Res       Date:  1997-01       Impact factor: 2.424

3.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 5.  Transforming growth factor beta in tissue fibrosis.

Authors:  W A Border; N A Noble
Journal:  N Engl J Med       Date:  1994-11-10       Impact factor: 91.245

6.  Correlation of fibrosis and transforming growth factor-beta type 2 levels in the eye.

Authors:  T B Connor; A B Roberts; M B Sporn; D Danielpour; L L Dart; R G Michels; S de Bustros; C Enger; H Kato; M Lansing
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  Role for carbohydrate structures in TGF-beta 1 latency.

Authors:  K Miyazono; C H Heldin
Journal:  Nature       Date:  1989-03-09       Impact factor: 49.962

8.  Growth factor localization in choroidal neovascular membranes of age-related macular degeneration.

Authors:  R Amin; J E Puklin; R N Frank
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-07       Impact factor: 4.799

9.  Immunolocalization of TGF-beta 1, TGF-beta 2, and TGF-beta 3 in the anterior segment of the human eye.

Authors:  L R Pasquale; M E Dorman-Pease; G A Lutty; H A Quigley; H D Jampel
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-01       Impact factor: 4.799

10.  CCR3 is a target for age-related macular degeneration diagnosis and therapy.

Authors:  Atsunobu Takeda; Judit Z Baffi; Mark E Kleinman; Won Gil Cho; Miho Nozaki; Kiyoshi Yamada; Hiroki Kaneko; Romulo J C Albuquerque; Sami Dridi; Kuniharu Saito; Brian J Raisler; Steven J Budd; Pete Geisen; Ariel Munitz; Balamurali K Ambati; Martha G Green; Tatsuro Ishibashi; John D Wright; Alison A Humbles; Craig J Gerard; Yuichiro Ogura; Yuzhen Pan; Justine R Smith; Salvatore Grisanti; M Elizabeth Hartnett; Marc E Rothenberg; Jayakrishna Ambati
Journal:  Nature       Date:  2009-06-14       Impact factor: 49.962

View more
  15 in total

1.  Interleukin-13 and age-related macular degeneration.

Authors:  Bo Fu; Zhe-Li Liu; Han Zhang; Feng Gu
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

2.  Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-γ agonist.

Authors:  Kazuhiro Kimura; Tomoko Orita; Yang Liu; Yang Yang; Kazuhiro Tokuda; Taishi Kurakazu; Takeshi Noda; Ryoji Yanai; Naoyuki Morishige; Atsunobu Takeda; Tatsuro Ishibashi; Koh-Hei Sonoda
Journal:  J Mol Med (Berl)       Date:  2015-05-08       Impact factor: 4.599

Review 3.  Molecular mechanisms of subretinal fibrosis in age-related macular degeneration.

Authors:  Keijiro Ishikawa; Ram Kannan; David R Hinton
Journal:  Exp Eye Res       Date:  2015-03-13       Impact factor: 3.467

4.  Aryl hydrocarbon receptor knock-out exacerbates choroidal neovascularization via multiple pathogenic pathways.

Authors:  Mayur Choudhary; Dmitri Kazmin; Peng Hu; Russell S Thomas; Donald P McDonnell; Goldis Malek
Journal:  J Pathol       Date:  2014-10-10       Impact factor: 7.996

5.  Balancing AhR-Dependent Pro-Oxidant and Nrf2-Responsive Anti-Oxidant Pathways in Age-Related Retinopathy: Is SERPINE1 Expression a Therapeutic Target in Disease Onset and Progression?

Authors:  Paul J Higgins
Journal:  J Mol Genet Med       Date:  2014-07-20

6.  TGF-β concentrations and activity are down-regulated in the aqueous humor of patients with neovascular age-related macular degeneration.

Authors:  Gian Marco Tosi; Giovanni Neri; Elena Caldi; Fiorella Fusco; Tommaso Bacci; Antonio Tarantello; Elisabetta Nuti; Davide Marigliani; Stefano Baiocchi; Claudio Traversi; Marcella Barbarino; Chiara M Eandi; Barbara Parolini; Lucia Mundo; Annalisa Santucci; Maurizio Orlandini; Federico Galvagni
Journal:  Sci Rep       Date:  2018-05-23       Impact factor: 4.379

Review 7.  EMT and EndMT: Emerging Roles in Age-Related Macular Degeneration.

Authors:  Daisy Y Shu; Erik Butcher; Magali Saint-Geniez
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

8.  AMPK Activation by 5-Amino-4-Imidazole Carboxamide Riboside-1-β-D-Ribofuranoside Attenuates Alkali Injury-Induced Corneal Fibrosis.

Authors:  Selikem Abla Nuwormegbe; Sun Woong Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

Review 9.  The Role of Inflammation in Age-Related Macular Degeneration.

Authors:  Wei Tan; Jingling Zou; Shigeo Yoshida; Bing Jiang; Yedi Zhou
Journal:  Int J Biol Sci       Date:  2020-09-23       Impact factor: 6.580

Review 10.  The Controversial Role of TGF-β in Neovascular Age-Related Macular Degeneration Pathogenesis.

Authors:  Gian Marco Tosi; Maurizio Orlandini; Federico Galvagni
Journal:  Int J Mol Sci       Date:  2018-10-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.